ADC Therapeutics Investor Relations Material

ADC Therapeutics SA is a biotechnology company specialized in the development of antibody-drug conjugates (ADCs) for the treatment of hematologic malignancies and solid tumors. Its proprietary technology focuses on highly potent, targeted therapies designed to significantly improve patient outcomes by selectively targeting and killing cancer cells. One of the key products offered by ADC Therapeutics is Zynlonta, a CD19-directed ADC for the treatment of certain types of B-cell lymphoma in adult patients. This focus on ADC technology highlights the company's commitment to advancing cancer treatment through innovation. The company is headquartered in Lausanne, Switzerland, and its shares are listed on the NYSE.